274 related articles for article (PubMed ID: 20129562)
1. Incidence and predictors of very late (>or=4 years) major cardiac adverse events in the DESIRE (Drug-Eluting Stents in the Real World)-Late registry.
Costa JR; Sousa A; Moreira AC; Costa RA; Cano M; Maldonado G; Campos C; Carballo M; Pavanello R; Sousa JE
JACC Cardiovasc Interv; 2010 Jan; 3(1):12-8. PubMed ID: 20129562
[TBL] [Abstract][Full Text] [Related]
2. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.
Simsek C; Magro M; Boersma E; Onuma Y; Nauta ST; Gaspersz MP; van der Giessen WJ; van Domburg RT; Serruys PW;
JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464
[TBL] [Abstract][Full Text] [Related]
3. 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial.
Vink MA; Dirksen MT; Suttorp MJ; Tijssen JG; van Etten J; Patterson MS; Slagboom T; Kiemeneij F; Laarman GJ
JACC Cardiovasc Interv; 2011 Jan; 4(1):24-9. PubMed ID: 21251625
[TBL] [Abstract][Full Text] [Related]
4. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
Leon MB; Nikolsky E; Cutlip DE; Mauri L; Liberman H; Wilson H; Patterson J; Moses J; Kandzari DE;
JACC Cardiovasc Interv; 2010 Oct; 3(10):1043-50. PubMed ID: 20965463
[TBL] [Abstract][Full Text] [Related]
5. Four-year follow-up of TYPHOON (trial to assess the use of the CYPHer sirolimus-eluting coronary stent in acute myocardial infarction treated with BallOON angioplasty).
Spaulding C; Teiger E; Commeau P; Varenne O; Bramucci E; Slama M; Beatt K; Tirouvanziam A; Polonski L; Stella PR; Clugston R; Fajadet J; de Boisgelin X; Bode C; Carrié D; Erglis A; Merkely B; Hosten S; Cebrian A; Wang P; Stoll HP; Henry P
JACC Cardiovasc Interv; 2011 Jan; 4(1):14-23. PubMed ID: 21251624
[TBL] [Abstract][Full Text] [Related]
6. Safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice: 12-month data from the E-Five registry.
Lotan C; Meredith IT; Mauri L; Liu M; Rothman MT;
JACC Cardiovasc Interv; 2009 Dec; 2(12):1227-35. PubMed ID: 20129549
[TBL] [Abstract][Full Text] [Related]
7. Outcomes after implantation of the TAXUS paclitaxel-eluting stent in saphenous vein graft lesions: results from the ARRIVE (TAXUS Peri-Approval Registry: A Multicenter Safety Surveillance) program.
Brilakis ES; Lasala JM; Cox DA; Berger PB; Bowman TS; Starzyk RM; Dawkins KD
JACC Cardiovasc Interv; 2010 Jul; 3(7):742-50. PubMed ID: 20650436
[TBL] [Abstract][Full Text] [Related]
8. Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8,061-patient XIENCE V United States study.
Naidu SS; Krucoff MW; Rutledge DR; Mao VW; Zhao W; Zheng Q; Wilburn O; Sudhir K; Simonton C; Hermiller JB
JACC Cardiovasc Interv; 2012 Jun; 5(6):626-35. PubMed ID: 22721657
[TBL] [Abstract][Full Text] [Related]
9. Drug eluting stents for the treatment of bare metal in-stent restenosis: long-term outcomes in real world practice.
Appleby CE; Khattar RS; Morgan K; Clarke B; Curzen N; Neyses L; Fath-Ordoubadi F
EuroIntervention; 2011 Jan; 6(6):748-53. PubMed ID: 21205600
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel- versus sirolimus-eluting stents for treatment of ST-segment elevation myocardial infarction: with analyses for diabetic and nondiabetic subpopulation.
Cho Y; Yang HM; Park KW; Chung WY; Choi DJ; Seo WW; Jeong KT; Chae SC; Lee MY; Hur SH; Chae JK; Seong IW; Yoon JH; Oh SK; Kim DI; Park KS; Rha SW; Jang YS; Bae JH; Hong TJ; Cho MC; Kim YJ; Jeong MH; Kim MJ; Park SK; Chae IH; Kim HS;
JACC Cardiovasc Interv; 2010 May; 3(5):498-506. PubMed ID: 20488406
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent).
Ellis SG; Stone GW; Cox DA; Hermiller J; O'Shaughnessy C; Mann T; Turco M; Caputo R; Bergin PJ; Bowman TS; Baim DS;
JACC Cardiovasc Interv; 2009 Dec; 2(12):1248-59. PubMed ID: 20129552
[TBL] [Abstract][Full Text] [Related]
12. 2-year results of the AUTAX (Austrian Multivessel TAXUS-Stent) registry beyond the SYNTAX (synergy between percutaneous coronary intervention with TAXUS and cardiac surgery) study.
Gyöngyösi M; Christ G; Lang I; Kreiner G; Sochor H; Probst P; Neunteufl T; Badr-Eslam R; Winkler S; Nyolczas N; Posa A; Leisch F; Karnik R; Siostrzonek P; Harb S; Heigert M; Zenker G; Benzer W; Bonner G; Kaider A; Glogar D;
JACC Cardiovasc Interv; 2009 Aug; 2(8):718-27. PubMed ID: 19695539
[TBL] [Abstract][Full Text] [Related]
13. A randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes mellitus: 4-year clinical outcomes of DES-DIABETES (drug-eluting stent in patients with DIABETES mellitus) trial.
Lee SW; Park SW; Kim YH; Yun SC; Park DW; Lee CW; Kang SJ; Rhee KS; Chae JK; Ko JK; Park JH; Lee JH; Choi SW; Jeong JO; Seong IW; Cho YH; Lee NH; Kim JH; Chun KJ; Kim HS; Park SJ
JACC Cardiovasc Interv; 2011 Mar; 4(3):310-6. PubMed ID: 21435609
[TBL] [Abstract][Full Text] [Related]
14. Long-term clinical results following stenting of the left main stem: insights from RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology Hospital) Registries.
Onuma Y; Girasis C; Piazza N; Garcia-Garcia HM; Kukreja N; Garg S; Eindhoven J; Cheng JM; Valgimigli M; van Domburg R; Serruys PW;
JACC Cardiovasc Interv; 2010 Jun; 3(6):584-94. PubMed ID: 20630451
[TBL] [Abstract][Full Text] [Related]
15. Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a substudy of the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials.
Garg S; Sarno G; Serruys PW; Rodriguez AE; Bolognese L; Anselmi M; De Cesare N; Colangelo S; Moreno R; Gambetti S; Monti M; Bristot L; Bressers M; Garcia-Garcia HM; Parrinello G; Campo G; Valgimigli M;
JACC Cardiovasc Interv; 2011 Jan; 4(1):66-75. PubMed ID: 21251631
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes after unrestricted implantation of everolimus-eluting stents.
Latib A; Ferri L; Ielasi A; Godino C; Chieffo A; Magni V; Bassanelli G; Sharp AS; Gerber R; Michev I; Carlino M; Airoldi F; Sangiorgi GM; Montorfano M; Colombo A
JACC Cardiovasc Interv; 2009 Dec; 2(12):1219-26. PubMed ID: 20129548
[TBL] [Abstract][Full Text] [Related]
17. Four-year clinical outcome of sirolimus- and paclitaxel-eluting stents compared to bare-metal stents for the percutaneous treatment of stable coronary artery disease.
Simsek C; Onuma Y; Magro M; de Boer S; Battes L; van Domburg RT; Boersma E; Serruys PW;
Catheter Cardiovasc Interv; 2010 Jul; 76(1):41-9. PubMed ID: 20310019
[TBL] [Abstract][Full Text] [Related]
18. 3-year follow-up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) trial.
Holmes DR; Teirstein PS; Satler L; Sketch MH; Popma JJ; Mauri L; Wang HP; Schleckser PA; Cohen SA;
JACC Cardiovasc Interv; 2008 Aug; 1(4):439-48. PubMed ID: 19463342
[TBL] [Abstract][Full Text] [Related]
19. A new generation of biodegradable polymer-coated sirolimus-eluting stents for the treatment of coronary artery disease: final 5-year clinical outcomes from the CREATE study.
Han YL; Zhang L; Yang LX; Liu HL; Qu P; Li WM; Jiang TM; Li SM; Jing QM; Zhang QY; Xu B; Li Y; Gao RL
EuroIntervention; 2012 Nov; 8(7):815-22. PubMed ID: 23171802
[TBL] [Abstract][Full Text] [Related]
20. Two-year follow-up of the Genous™ endothelial progenitor cell capturing stent versus the Taxus Liberté stent in patients with de novo coronary artery lesions with a high-risk of restenosis: a randomized, single-center, pilot study.
Beijk MA; Klomp M; van Geloven N; Koch KT; Henriques JP; Baan J; Vis MM; Tijssen JG; Piek JJ; de Winter RJ
Catheter Cardiovasc Interv; 2011 Aug; 78(2):189-95. PubMed ID: 21542109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]